JP2017527618A - 肺サルコイドーシスの治療方法 - Google Patents

肺サルコイドーシスの治療方法 Download PDF

Info

Publication number
JP2017527618A
JP2017527618A JP2017531987A JP2017531987A JP2017527618A JP 2017527618 A JP2017527618 A JP 2017527618A JP 2017531987 A JP2017531987 A JP 2017531987A JP 2017531987 A JP2017531987 A JP 2017531987A JP 2017527618 A JP2017527618 A JP 2017527618A
Authority
JP
Japan
Prior art keywords
treatment
patient
dnase
pulmonary sarcoidosis
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527618A5 (cg-RX-API-DMAC7.html
Inventor
バーンズ バリー
バーンズ バリー
Original Assignee
ゴッサム バイオファーマシューティカルズ，インコーポレイティド
ゴッサム バイオファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴッサム バイオファーマシューティカルズ，インコーポレイティド, ゴッサム バイオファーマシューティカルズ，インコーポレイティド filed Critical ゴッサム バイオファーマシューティカルズ，インコーポレイティド
Publication of JP2017527618A publication Critical patent/JP2017527618A/ja
Publication of JP2017527618A5 publication Critical patent/JP2017527618A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2017531987A 2014-09-08 2015-09-04 肺サルコイドーシスの治療方法 Pending JP2017527618A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047361P 2014-09-08 2014-09-08
US62/047,361 2014-09-08
PCT/US2015/048606 WO2016040169A2 (en) 2014-09-08 2015-09-04 Methods of treating pulmonary sarcoidosis

Publications (2)

Publication Number Publication Date
JP2017527618A true JP2017527618A (ja) 2017-09-21
JP2017527618A5 JP2017527618A5 (cg-RX-API-DMAC7.html) 2019-02-14

Family

ID=54697634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531987A Pending JP2017527618A (ja) 2014-09-08 2015-09-04 肺サルコイドーシスの治療方法

Country Status (11)

Country Link
US (2) US20170368150A1 (cg-RX-API-DMAC7.html)
EP (1) EP3191090A2 (cg-RX-API-DMAC7.html)
JP (1) JP2017527618A (cg-RX-API-DMAC7.html)
KR (1) KR20170045750A (cg-RX-API-DMAC7.html)
CN (1) CN107249621A (cg-RX-API-DMAC7.html)
AU (1) AU2015315455A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017004533A2 (cg-RX-API-DMAC7.html)
CA (1) CA2960622A1 (cg-RX-API-DMAC7.html)
IL (1) IL250980A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017002948A (cg-RX-API-DMAC7.html)
WO (1) WO2016040169A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
SG11202001445XA (en) 2017-08-18 2020-03-30 Neutrolis Inc Engineered dnase enzymes and use in therapy
SG11202103426XA (en) 2018-10-08 2021-05-28 Neutrolis Inc Engineering of dnase enzymes for manufacturing and therapy
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
KR20210137061A (ko) * 2019-02-22 2021-11-17 실라 세라퓨틱 인크. 흡입성 치료제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
JP2011529953A (ja) * 2008-08-07 2011-12-15 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
JP2007230919A (ja) * 2006-03-01 2007-09-13 Ki Pharma Kk 美白剤
PL2173708T3 (pl) * 2007-08-03 2011-08-31 Ucb Pharma Sa Pochodne sulfanylowe i ich zastosowanie jako związków pośrednich do syntezy
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
GB201002224D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
JP2011529953A (ja) * 2008-08-07 2011-12-15 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. CLIN. PHARMACOL., (2012), 52, [4], P.530-542, JPN6019023782, ISSN: 0004224302 *
PROC. NATL. ACAD. SCI. USA, (1990), 87, [23], P.9188-9192, JPN6019023783, ISSN: 0004224303 *

Also Published As

Publication number Publication date
BR112017004533A2 (pt) 2018-05-08
CN107249621A (zh) 2017-10-13
US20160067317A1 (en) 2016-03-10
KR20170045750A (ko) 2017-04-27
CA2960622A1 (en) 2016-03-17
IL250980A0 (en) 2017-04-30
WO2016040169A3 (en) 2016-05-26
WO2016040169A2 (en) 2016-03-17
EP3191090A2 (en) 2017-07-19
US9402884B2 (en) 2016-08-02
MX2017002948A (es) 2017-08-15
US20170368150A1 (en) 2017-12-28
AU2015315455A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
JP2017527618A (ja) 肺サルコイドーシスの治療方法
Solomonov et al. Pulmonary hemorrhage: a novel mode of therapy
EP3191513B1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
AU2014249531B2 (en) Use of levocetirizine and montelukast in the treatment of traumatic injury
Gupta et al. Comparison of the efficacy of platelet-rich plasma (PRP) and local corticosteroid injection in periarthritis shoulder: a prospective, randomized, open, blinded end-point (PROBE) study
Homøe et al. Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial
Casale et al. Post-operative nebulized sodium hyaluronate versus spray after functional endoscopic sinus surgery for chronic rhinosinusitis
Fay et al. Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and topical trametinib
Amorós et al. Central giant cell granuloma: off-label treatment with Denosumab in a patient with Noonan syndrome
Oz et al. Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab
Umesh et al. Does Zoledronic Acid Provide a Good Clinical Outcome in Patients With Chronic Back Pain Associated With Vertebral Osteoporosis?
Kim et al. The efficacy of cotton ball packing after endoscopic sinus surgery: a prospective, randomized, controlled trial
Macaya et al. Recommendations for the multidisciplinary management of tuberous sclerosis complex
JP7536364B2 (ja) 骨軟部腫瘍の治療用医薬組成物
Lee et al. Eye Globe Rupture Caused by Dental Implant–Related Maxillary Sinusitis
Pendolino et al. The role of large cavity sinus surgery in the management of chronic rhinosinusitis in non-steroidal anti-inflammatory drug exacerbated respiratory disease: a single-centre experience and long-term outcomes
JEICAN et al. Rehabilitation of patients with chronic rhinosinusitis after functional endoscopic sinus surgery
Lal et al. Antifungal treatment and chronic rhinosinusitis
RU2499597C2 (ru) Способ лечения и профилактики назальной обструкции у больных полипозным риносинуситом
Hadi et al. The Effect of Submucous Dexamethasone Injection on the Post-Operative Sequelae After Impacted Third Molar Surgery.
Inoue et al. Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series
Vaidyanathan et al. Rhinocerebral mucormycosis: A series of 3 cases.
Abdelrahman et al. Effect Of Platelet Rich Fibrin On Wound Healing And Hemostasis After Sinus Surgery In Patients With Sino Nasal Polyposis
Kikuchi et al. Selection of abatacept for patients with rheumatoid arthritis aged 70 years or older
CN109939223B (zh) 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303